SOT102, a novel CLDN18.2-targeting antibody-drug conjugate, exhibits strong therapeutic potential in solid tumors

Abstract Background Patients with gastric and pancreatic cancers, as well as other solid tumors including ovarian, lung, liver, and colon cancers, often lack effective therapeutic options. Claudin 18.2 (CLDN18.2) is a tumor-associated target that is predominantly expressed in gastric and pancreatic...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Iva Valentová, Lenka Kyrych Sadílková, Lukas Bammert, Lorenz Waldmeier, Roger Beerli, Ilona Procházková, Filip Jabůrek, Tatiana Spitzová, Eliška Kohelová, Kati Räsänen, Ulrich Moebius, Radek Špíšek
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2026-05-01
Saila:	BMC Cancer
Gaiak:	Claudin 18.2 Antibody-drug conjugate Gastric cancer Pancreatic cancer Solid tumor
Sarrera elektronikoa:	https://doi.org/10.1186/s12885-026-16185-x
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!